Advertisement
The Leading Source for Pharmaceutical & Biopharmaceutical Manufacturing News
Subscribe to Pharmaceutical Processing
View Sample

FREE Daily Email Newsletter

Astellas and Medivation to Co-Develop andCo-Commercialize MDV3100 for the Treatment of Prostate Cancer

October 27, 2009 4:38 am | News | Comments

Astellas PharmaInc. and Medivation, Inc. announced today thatthey have entered into a global agreement to develop and commercializeMDV3100, Medivation's investigational drug for the treatment of prostatecancer.

TOPICS:

Microbix And Hunan Biopharmaceutical To Build Asia's Largest Influenza Vaccine Facility

October 27, 2009 4:34 am | News | Comments

Microbix, a developerof a patented technology that doubles the output of influenza vaccineproduction, announced today it has signed a joint venture agreement with theHunan Biopharmaceutical Co. Ltd.

TOPICS:

BioMarin Acquires Huxley Pharmaceuticals, Inc.

October 27, 2009 4:30 am | News | Comments

BioMarin Pharmaceutical Inc. has announced that it has acquired Huxley Pharmaceuticals, Inc. (Huxley), which has rights to a proprietary form of 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate, for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS).

TOPICS:
Advertisement

GSK and Genmab Receive Accelerated Approval for Arzerra™

October 27, 2009 4:22 am | News | Comments

GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) have announced the accelerated approval of ArzerraTM (ofatumumab) from the FDA for use in patients with chronic lymphocytic leukemia (CLL) that is refractory to fludarabine and alemtuzumab.

TOPICS:

India's Ranbaxy Posts Profit Despite US Import Ban

October 26, 2009 5:28 am | News | Comments

ERIKA KINETZ AP Business Writer MUMBAI, India (AP) — India's largest drug maker, Ranbaxy Laboratories Ltd., on Monday reported a $24 million quarterly profit as emerging market sales and cost cutting helped compensate for sharply falling U.S. sales. Net profit for the three months ending Sept.

TOPICS:

Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation

October 26, 2009 5:26 am | News | Comments

Cephalon, Inc. and BioAssets Development Corporation, aprivately held biopharmaceutical company, today announced that the companieshave signed an agreement that will provide Cephalon with an option to acquireBDC.

TOPICS:

Allergan Announces Victory in Brimonidine Patent Infringement Case

October 26, 2009 5:22 am | News | Comments

Allergan, Inc. has announced that the United States District Court for the District of Delaware ruled in favor of Allergan, Inc. in its patent infringement suit against Exela PharmSci, Inc., Exela PharmSci Pvt., Ltd. ("Exela"), Apotex, Inc. and Apotex Corp.

TOPICS:

European Union Approves Merck Takeover of Schering-Plough

October 26, 2009 5:01 am | News | Comments

RAF CASERT Associated Press Writer BRUSSELS (AP) — The European Union approved Merck & Co.'s proposed takeover of Schering-Plough, which would create the second-biggest global producer of prescription medicines.

TOPICS:
Advertisement

HHS' Sebelius: Ample Flu Vaccine Will Be Available

October 26, 2009 4:57 am | News | Comments

WASHINGTON (AP) — Health and Human Services Secretary Kathleen Sebelius said Monday the swine flu vaccine "is coming out the door as fast as it comes off the production line." But at the same time, she acknowledged delays in getting a sufficient supply for all those demanding it.

TOPICS:

South Carolina Attorney General Reaches $45M Deal with Lilly

October 26, 2009 4:54 am | News | Comments

MEG KINNARD Associated Press Writer COLUMBIA, S.C. (AP) — South Carolina's attorney general said Friday the state has reached a $45 million settlement with drug maker Eli Lilly & Co.

TOPICS:

Rhode Island Tracking Swine Flu Through Electronic Records - First State To Do So.

October 26, 2009 4:50 am | News | Comments

ERIC TUCKER Associated Press Writer PROVIDENCE, R.I. (AP) — State health officials are tracking the spread of swine flu through electronic prescription records, developing what they believe is a model that could help doctors more easily identify and respond to an outbreak of the illness.

Germany's Merck Says Q3 Net Income Falls 28%

October 26, 2009 4:39 am | News | Comments

GEORGE FREY AP Business Writer FRANKFURT (AP) — German drug and chemical maker Merck KGaA saw net income fall 28 percent in the third quarter despite higher sales, as it spent more on product development and took a one-time charge related to its 2007 acquisition of Serono.

TOPICS:

Emergency Use Authorization Granted For BioCryst's Peramivir

October 26, 2009 4:33 am | News | Comments

BioCrystPharmaceuticals, Inc. recently announced that the FDA, in response to a request from the U.S. Centers forDisease Control and Prevention (CDC), has issued an emergency useauthorization (EUA) for the investigational anti-viral drug intravenous (i.v.

TOPICS:

GAO: FDA Fails to Follow Up on Unproven Drugs

October 26, 2009 4:28 am | News | Comments

MATTHEW PERRONE AP Business Writer WASHINGTON (AP) — The Food and Drug Administration has allowed drugs for cancer and other diseases to stay on the market even when follow-up studies showed they didn't extend patients' lives, say congressional investigators.

TOPICS:

FDA Determines VYVANSE was Properly Granted Five-Year Market Exclusivity

October 26, 2009 4:23 am | News | Comments

Shire plc announced that the FDA, following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading